Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Welcome to APCCC 2021
ESMO 2021 Roundup
New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma
PARP inhibitors in prostate cancer: Case based testing and clinical decisions
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients
Should every transplant eligible NDMM patient receive a transplant?
Vaccinations in myeloma patients including for COVID-19